295 related articles for article (PubMed ID: 32724113)
1. Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testing.
Nanki Y; Chiyoda T; Hirasawa A; Ookubo A; Itoh M; Ueno M; Akahane T; Kameyama K; Yamagami W; Kataoka F; Aoki D
Sci Rep; 2020 Jul; 10(1):12581. PubMed ID: 32724113
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.
Secord AA; Barnett JC; Ledermann JA; Peterson BL; Myers ER; Havrilesky LJ
Int J Gynecol Cancer; 2013 Jun; 23(5):846-52. PubMed ID: 23666017
[TBL] [Abstract][Full Text] [Related]
3. Screening drug effects in patient-derived cancer cells links organoid responses to genome alterations.
Jabs J; Zickgraf FM; Park J; Wagner S; Jiang X; Jechow K; Kleinheinz K; Toprak UH; Schneider MA; Meister M; Spaich S; Sütterlin M; Schlesner M; Trumpp A; Sprick M; Eils R; Conrad C
Mol Syst Biol; 2017 Nov; 13(11):955. PubMed ID: 29180611
[TBL] [Abstract][Full Text] [Related]
4. Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors.
Maru Y; Tanaka N; Itami M; Hippo Y
Gynecol Oncol; 2019 Jul; 154(1):189-198. PubMed ID: 31101504
[TBL] [Abstract][Full Text] [Related]
5. Ex vivo chemosensitivity assay using primary ovarian cancer organoids for predicting clinical response and screening effective drugs.
Ito Y; Kondo J; Masuda M; Matsuzaki S; Onuma K; Kanda M; Watanabe Y; Sakaguchi H; Yoshino K; Ueda Y; Kamiura S; Kimura T; Inoue M
Hum Cell; 2023 Mar; 36(2):752-761. PubMed ID: 36474106
[TBL] [Abstract][Full Text] [Related]
6. Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.
Lambrechts S; Smeets D; Moisse M; Braicu EI; Vanderstichele A; Zhao H; Van Nieuwenhuysen E; Berns E; Sehouli J; Zeillinger R; Darb-Esfahani S; Cacsire Castillo-Tong D; Lambrechts D; Vergote I
Eur J Cancer; 2016 Jan; 53():51-64. PubMed ID: 26693899
[TBL] [Abstract][Full Text] [Related]
7. Developing Organoids from Ovarian Cancer as Experimental and Preclinical Models.
Maenhoudt N; Defraye C; Boretto M; Jan Z; Heremans R; Boeckx B; Hermans F; Arijs I; Cox B; Van Nieuwenhuysen E; Vergote I; Van Rompuy AS; Lambrechts D; Timmerman D; Vankelecom H
Stem Cell Reports; 2020 Apr; 14(4):717-729. PubMed ID: 32243841
[TBL] [Abstract][Full Text] [Related]
8. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
Alkema NG; Wisman GB; van der Zee AG; van Vugt MA; de Jong S
Drug Resist Updat; 2016 Jan; 24():55-69. PubMed ID: 26830315
[TBL] [Abstract][Full Text] [Related]
9. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
[TBL] [Abstract][Full Text] [Related]
10. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Pujade-Lauraine E; Ledermann JA; Selle F; Gebski V; Penson RT; Oza AM; Korach J; Huzarski T; Poveda A; Pignata S; Friedlander M; Colombo N; Harter P; Fujiwara K; Ray-Coquard I; Banerjee S; Liu J; Lowe ES; Bloomfield R; Pautier P;
Lancet Oncol; 2017 Sep; 18(9):1274-1284. PubMed ID: 28754483
[TBL] [Abstract][Full Text] [Related]
11. Short-term organoid culture for drug sensitivity testing of high-grade serous carcinoma.
Chen H; Gotimer K; De Souza C; Tepper CG; Karnezis AN; Leiserowitz GS; Chien J; Smith LH
Gynecol Oncol; 2020 Jun; 157(3):783-792. PubMed ID: 32253045
[TBL] [Abstract][Full Text] [Related]
12. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity.
Kopper O; de Witte CJ; Lõhmussaar K; Valle-Inclan JE; Hami N; Kester L; Balgobind AV; Korving J; Proost N; Begthel H; van Wijk LM; Revilla SA; Theeuwsen R; van de Ven M; van Roosmalen MJ; Ponsioen B; Ho VWH; Neel BG; Bosse T; Gaarenstroom KN; Vrieling H; Vreeswijk MPG; van Diest PJ; Witteveen PO; Jonges T; Bos JL; van Oudenaarden A; Zweemer RP; Snippert HJG; Kloosterman WP; Clevers H
Nat Med; 2019 May; 25(5):838-849. PubMed ID: 31011202
[TBL] [Abstract][Full Text] [Related]
13. A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids.
Senkowski W; Gall-Mas L; Falco MM; Li Y; Lavikka K; Kriegbaum MC; Oikkonen J; Bulanova D; Pietras EJ; Voßgröne K; Chen YJ; Erkan EP; Dai J; Lundgren A; Grønning Høg MK; Larsen IM; Lamminen T; Kaipio K; Huvila J; Virtanen A; Engelholm L; Christiansen P; Santoni-Rugiu E; Huhtinen K; Carpén O; Hynninen J; Hautaniemi S; Vähärautio A; Wennerberg K
Dev Cell; 2023 Jun; 58(12):1106-1121.e7. PubMed ID: 37148882
[TBL] [Abstract][Full Text] [Related]
14. Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening.
Kim M; Mun H; Sung CO; Cho EJ; Jeon HJ; Chun SM; Jung DJ; Shin TH; Jeong GS; Kim DK; Choi EK; Jeong SY; Taylor AM; Jain S; Meyerson M; Jang SJ
Nat Commun; 2019 Sep; 10(1):3991. PubMed ID: 31488816
[TBL] [Abstract][Full Text] [Related]
15. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
16. Current Status of Patient-Derived Ovarian Cancer Models.
Maru Y; Hippo Y
Cells; 2019 May; 8(5):. PubMed ID: 31130643
[TBL] [Abstract][Full Text] [Related]
17. Preclinical investigation of patient-derived cervical cancer organoids for precision medicine.
Seol HS; Oh JH; Choi E; Kim S; Kim H; Nam EJ
J Gynecol Oncol; 2023 May; 34(3):e35. PubMed ID: 36659831
[TBL] [Abstract][Full Text] [Related]
18. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition.
Lheureux S; Bruce JP; Burnier JV; Karakasis K; Shaw PA; Clarke BA; Yang SY; Quevedo R; Li T; Dowar M; Bowering V; Pugh TJ; Oza AM
J Clin Oncol; 2017 Apr; 35(11):1240-1249. PubMed ID: 28221868
[TBL] [Abstract][Full Text] [Related]
19. Head and neck cancer organoids established by modification of the CTOS method can be used to predict in vivo drug sensitivity.
Tanaka N; Osman AA; Takahashi Y; Lindemann A; Patel AA; Zhao M; Takahashi H; Myers JN
Oral Oncol; 2018 Dec; 87():49-57. PubMed ID: 30527243
[TBL] [Abstract][Full Text] [Related]
20. Patient-derived organoids in ovarian cancer: Current research and its clinical relevance.
Kumar S; Raina M; Tankay K; Ingle GM
Biochem Pharmacol; 2023 Jul; 213():115589. PubMed ID: 37196684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
